Last updated:
Psilocybe Azurescens
"Flying Saucer, Indigo Psilocybe, Blue Runners, Blue Angels"
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/Azzies1_new-800x450.webp)
Scientific Classification
About
Psilocybe azurescens, widely known as the Flying Saucer Mushroom, is one of the most potent naturally occurring psychedelic mushrooms, containing exceptionally high levels of psilocybin and psilocin. Native to the Pacific Northwest of the United States, particularly Oregon and Washington, this mushroom is known for its caramel-colored cap, strong bluing reaction when bruised, and intense psychoactive effects.
History
Discovered and officially described in 1996 by Paul Stamets and colleagues, Psilocybe azurescens quickly gained fame in psychonaut and mycology circles due to its extreme potency. The nickname “Flying Saucer” refers both to the shape of its broad, convex cap and the powerful "out-of-body" experiences often reported by users.
Although it is not traditionally used in indigenous ceremonies like some other Psilocybe species, it has found popularity in contemporary psychedelic exploration, especially among those seeking profound introspective or spiritual experiences.
Overview
This species grows naturally on decaying wood, dunes, and plant debris along coastal environments, especially near dune grasses. Its cap ranges from 3–10 cm, often convex with a central bump (umbonate), and fades from chestnut-brown to light yellowish with drying. The stipe (stem) is long, often twisted, and bruises deep blue when handled—indicative of its psilocybin content.
With psilocybin levels up to 1.8% by dry weight, Psilocybe azurescens is among the most potent entheogens. Effects can be deeply introspective, euphoric, and at times overwhelming, making dosage control essential. It remains illegal in many jurisdictions but is studied for its potential therapeutic use in treating depression, PTSD, and addiction.
Physical Characteristics
Caps:
Medium to large-sized with a conical shape, initially caramel-brown and becoming light brown with age
Gills:
Initially grayish, maturing to dark purple-brown
Cognitive Effects
Creativity
Many individuals report heightened creativity and a sense of increased ideational fluency while under the influence of psilocybin. This may include enhanced problem-solving abilities, novel insights, and out-of-the-box thinking.
Psychoactive Effects
Hallucinogenic
Induces hallucinations, altering perception of reality.
Euphoric
Produces intense feelings of happiness or excitement.
Pharmacology
Helps With
Depression
May provide relief from symptoms of depression.
Anxiety
May help reduce symptoms of anxiety.
PTSD
May help alleviate symptoms of PTSD.
Addiction
May help reduce addictive behaviors.
OCD
May help reduce symptoms of OCD.
Pain
Microdosing psilocybin has been shown to help with certain types of pain
Migraines
Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines.4 A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.
Possible Side Effects
Nausea
May cause stomach discomfort or feelings of being sick.
Paranoid
May cause excessive feelings of fear or distress.
Paralysis
When consumed in large quantities, may cause temporary paralysis.
Grow at Home
Start your cultivation journey with quality grow kits from verified vendors
Chemical Constituents
Medicinal Chemistry
Similar Species
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeCyanescens-1_new-400x400.webp)
Species: Psilocybe Cyanescens
Edibility: Psychoactive
Key Differences: Psilocybe Cyanescens has a more wavy cap compared to the convex to subumbonate cap of Psilocybe Azurescens.
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeCyanescens-1_new-400x400.webp)
Species: Psilocybe Cyanescens
Edibility: Psychoactive
Mushroom Ratings
0.0
Based on 0 Reviews
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
References
- Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., & Gordon, E. M. (2024). Psilocybin desynchronizes the human brain. .
- Sekssaoui, M. (2024). Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. .
- Ley, L. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. .
- Bae, S. (2023). Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. .
- Schindler, E. (2022 ). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. .
- Barrett, F. (2022). Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. .
- Desai, S. (2022). Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study. .
- Rucker, J. (2021). Psilocybin: From Serendipity to Credibility?. .
- Schindler, E. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. .
- Raval, N. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. .